Meril Italy v SWAT Medical (CoA, 5 May 2025)
| Date | 5 May 2025 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Decision By Default |
| Registry reference | ORD_21232/2025 · ORD_21233/2025 |
| Parties | Meril Italy v. SWAT Medical AB and Respondent |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In a decision of 5 May 2025 (UPC_CoA_634/2024, APL_58930/2025), the Court of Appeal, on an appeal by Meril Italy, sets aside the Paris Central Division’s order of 14 October 2024 (ORD_36095/2024, UPC_CFI_255/2024) that had granted a European patent attorney, a board member of SWAT Medical, and that company access to the written pleadings and evidence in the revocation action (ACT_551308/2023) between Meril Italy and Edwards Lifesciences concerning EP 3 646 825, and dismisses the access application (App_33486/2024). The decision lays down two useful rules: a member of the public seeking access under Rule 262.1(b) must be represented, and no costs are awarded in such proceedings.
Question
Is a Statement of response valid when signed by an applicant for access who may neither represent himself nor the co-applicant company, and what decision must the Court then give. Can costs be awarded in proceedings for access to the register?
Decision
The named representative never appeared or signed the Statement of response, so no valid Statement of response was lodged (paragraphs 11 to 17). Rule 235.3 is a lex specialis. The reasoned decision it allows, even of the Court’s own motion, is effectively a decision by default, so the application to set aside under Rule 356.1 applies mutatis mutandis (paragraphs 18 to 23). Since every applicant before the UPC must be represented unless the Rules waive the requirement, access could not be granted to unrepresented members of the public (paragraph 24). Access to the register is an administrative, non-adversarial matter, so no costs are awarded, save for unnecessary costs under Art. 69(3) UPCA, which did not arise here (paragraphs 25 to 34).
Key points for practice
- An application for access under Rule 262.1(b) requires an authorised representative. A patent attorney acting for himself or for the company on whose board he sits cannot represent himself (paragraphs 8 and 24).
- Practical point: a party resisting an access application cannot expect to recover its costs, and the defaulting party has one month from service to apply to set the decision aside (Rule 356.1).
Provisions applied
- Agreement on a Unified Patent Court
- Arts 10, 45, 47 and 69
- Statute of the Court
- Art. 37(1)
- Rules of Procedure
- Rules 8, 235.3, 236, 262.1(b), 262.2, 293, 355, 356, 357 and 370
- Case law cited
- Ocado v Autostore, Court of Appeal, 8 February 2024, Ocado v Autostore, Court of Appeal, 10 April 2024
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: UPC Court of Appeal.
Dhenne Avocats blog: UPC Appeals: What the Numbers Show.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
UPC_CFI_255/2024Parties
- claimantMeril ItalyFollow this party
- defendantSWAT Medical AB and Respondent3 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Decision By Default
- Outcome (Dhenne Avocats summary)
- La cour d’appel annule l’ordonnance d’accès et rejette la demande : un membre du public non représenté ne peut obtenir l’accès de la règle 262.1(b), et aucun frais n’est alloué dans cette procédure.
- Appeal
- Decision of the Court of Appeal (first instance cited: UPC_CFI_255/2024).
- Instance
- Court of Appeal decision.
Patents mentioned
EP 3 646 825mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Meril Italy v SWAT Medical (CoA, 12 February 2025) cited in this record
- Ocado Innovation v Autostore (CoA, 10 April 2024) cited in this record
- Ocado Innovation v Respondent (CoA, 8 February 2024) cited in this record
- Meril v SWAT Medical (CoA, 5 May 2025) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 646 825A system comprising a prosthetic valve and a delivery catheter recorded proprietor: Edwards Lifesciences Corp | Mentioned in the analysis (role not qualified) Also mentioned in 32 other decision(s): Edwards Lifesciences v Meril Life Sciences (CFI, 15 November 2024) · Meril Italy v Edwards Lifesciences (CFI, 19 July 2024) · Meril v Edwards Lifesciences (CFI, 19 July 2024) · Meril Italy v Edwards Lifesciences (CoA, 25 November 2025) · Edwards Lifesciences v Sintec (CFI, 5 September 2025) · Meril v SWAT Medical (CoA, 5 May 2025) · Meril Life Sciences v SWAT Medical (CoA, 5 May 2025) · Meril v Edwards Lifesciences (CoA, 18 April 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.